The FDA has issued emergency use authorizations for two monoclonal antibody treatments for COVID-19 – one produced by Eli Lilly and another by Regeneron. As science correspondent Richard Harris explains, emergency use authorization doesn't assure that these new drugs are effective, but that their potential benefits are likely to outweigh the risks. So today, we get to the bottom of how this type of treatment works and if they'll really make a difference.

Email the show your questions, coronavirus or otherwise, at [email protected].

To manage podcast ad preferences, review the links below:

See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy